These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 1500026

  • 1. Preoperative serum CA-125 levels in borderline tumors of the ovary.
    Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp RC, Bell DA.
    Gynecol Oncol; 1992 Aug; 46(2):226-9. PubMed ID: 1500026
    [Abstract] [Full Text] [Related]

  • 2. Epithelial ovarian tumors of borderline malignancy.
    Rice LW, Berkowitz RS, Mark SD, Yavner DL, Lage JM.
    Gynecol Oncol; 1990 Nov; 39(2):195-8. PubMed ID: 2227595
    [Abstract] [Full Text] [Related]

  • 3. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
    Gundogdu F, Soylu F, Erkan L, Tatli O, Mavi S, Yavuzcan A.
    Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
    [Abstract] [Full Text] [Related]

  • 4. Epithelial ovarian carcinoma of low malignant potential.
    Darai E, Teboul J, Walker F, Benifla JL, Meneux E, Guglielmina JN, Pennehouat G, Renolleau C, Sebban E, Madelenat P.
    Eur J Obstet Gynecol Reprod Biol; 1996 Jun; 66(2):141-5. PubMed ID: 8735736
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY, Shen K, Tao T, Yang JX, Xiang Y, Huang HF, Wu M, Pan LY, Lang JH.
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [Abstract] [Full Text] [Related]

  • 7. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG.
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [Abstract] [Full Text] [Related]

  • 8. [The clinicopathological features and risk factors of recurrence in patients with mucinous borderline ovarian tumors].
    Sun L, Song Y, Li N, Yuan GW, Sun YC, Li N, Ma SK, Zhang X, Wu LY.
    Zhonghua Zhong Liu Za Zhi; 2017 Aug 23; 39(8):589-594. PubMed ID: 28835081
    [Abstract] [Full Text] [Related]

  • 9. CA 125 measurement and ultrasonography in borderline tumors of the ovary.
    Gotlieb WH, Soriano D, Achiron R, Zalel Y, Davidson B, Kopolovic J, Novikov I, Ben-Baruch G.
    Am J Obstet Gynecol; 2000 Sep 23; 183(3):541-6. PubMed ID: 10992171
    [Abstract] [Full Text] [Related]

  • 10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr 23; 42(4):227-32. PubMed ID: 17631760
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
    Prat J, De Nictolis M.
    Am J Surg Pathol; 2002 Sep 23; 26(9):1111-28. PubMed ID: 12218568
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
    Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L, Friese K, Stieber P, Burges A.
    Clin Chem Lab Med; 2009 Sep 23; 47(5):537-42. PubMed ID: 19317653
    [Abstract] [Full Text] [Related]

  • 16. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
    Lee KR, Scully RE.
    Am J Surg Pathol; 2000 Nov 23; 24(11):1447-64. PubMed ID: 11075847
    [Abstract] [Full Text] [Related]

  • 17. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG, Gershenson DM, Malpica A, Deavers M.
    Am J Surg Pathol; 2006 Nov 23; 30(11):1367-71. PubMed ID: 17063075
    [Abstract] [Full Text] [Related]

  • 18. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas.
    Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, Lopez JJ, Ballesta A.
    Tumour Biol; 1992 Nov 23; 13(5-6):278-86. PubMed ID: 1290025
    [Abstract] [Full Text] [Related]

  • 19. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
    Kolwijck E, Thomas CM, Bulten J, Massuger LF.
    Int J Gynecol Cancer; 2009 Nov 23; 19(8):1335-8. PubMed ID: 20009886
    [Abstract] [Full Text] [Related]

  • 20. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma.
    Zurawski VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC, Ritts RE, Malkasian G.
    Gynecol Oncol; 1988 May 23; 30(1):7-14. PubMed ID: 2452773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.